# A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05417321/  
OnCo record `nct05417321` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HB0036 in non-small-cell lung cancer, run by Shanghai Huaota Biopharmaceutical Co., Ltd., now recruiting.

## Summary

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05417321 by Shanghai Huaota Biopharmaceutical Co., Ltd., with 80 participants planned, started 2022-08-25 and due to reach its primary completion in 2025-08-01. Interventions recorded: HB0036.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05417321
- Phase: 1/2
- Setting: A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
- Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT05417321: https://clinicaltrials.gov/study/NCT05417321

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [HB0036](https://onco.cc/drugs/hb0036/)

---
JSON: https://onco.cc/api/v1/entities/nct05417321.json